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Abstract 
In gynecologic oncology, ovarian cancer is the second leading cancer with highest 
mortality rate. Since most of ovarian cancer patients are diagnosed at advanced stage 
occurred with metastatic tumors, chemotherapy is a necessary treating procedure after the 
aggressive surgery which removes the patient’s primary ovary tumor (Primary 
cytoreduction). However, currently, no method is able to effectively and efficiently 
predict the tumor response to the chemotherapy at early stage (i.e. 4-6 weeks after the 
treatment). This study aims to investigate whether using quantitative image features 
computed from CT images enables to more accurately predict response of ovarian cancer 
patients to chemotherapy. During the experiment, we retrospectively assembled a dataset 
involving 91 patients. Each patient had two sets of pre-and post-therapy (4-6 weeks 
follow up) CT images. A computer-aided detection scheme was then developed, which is 
able segment the metastatic tumors and computed image features. Next, we built two 
initial feature pools using image features computed from pre-therapy CT images only and 
image feature difference computed from both pre- and post-therapy images. The 
predicting performance of each feature was evaluated using the area under ROC curve, 
which is based on the criteria 6-month progression-free survival (PFS).  Among these 
features, the optimal feature cluster was determined and an equal-weighted fusion method 
was used to generate a new image marker to predict PFS of the patients.  The results 
indicate that the highest single feature AUC values are achieved as 0.6842 ± 0.0557 and 
0.7705 ± 0.0495 respectively, which are computed from pre-therapy CT images only and 
both pre- and post-therapy CT images. When applying fusion-based image markers, AUC 
values significantly increased to 0.8103 ± 0.0447 and 0.8292 ±0.0431 (p < 0.05), 
x 
 
respectively. This study demonstrated that it is feasible to predict patients’ early stage 
response to chemotherapy using quantitative image features computed from pre-therapy 
CT images. However, we can significantly improve the prediction performance when 
adding information from the 4-6 week follow up CT images.   
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Chapter 1: Introduction 
Ovarian Cancer 
Ovarian cancer is the second most common cancer in gynecologic oncology. In 
2016, approximately 22,280 newly diagnosed cases and 14,240 deaths are estimated in 
United States [1]. Given that early symptoms originating from ovaries are hard to be 
detected and even more likely to be confused for something far less serious, routine pelvic 
examinations are not able to effectively detect ovarian cancer. As a result, approximately 
70% of ovarian cancer patients’ are diagnosed at an advanced stage [2] with metastatic 
tumors, and ovarian cancer is the leading cause of death among all the gynecologic 
cancers. As indicated in Figure 1, the five-year survival rates for stage III and IV epithelial 
ovarian cancer patients are only 36% and 17% respectively [3]. For the advanced stage 
ovarian cancer patients, an aggressive surgery is first operated to remove the primary 
ovarian tumors (Primary cytoreduction) and chemotherapy is then followed to control the 
metastatic tumors. Since ovarian cancer is highly heterogeneous, and the metastasized 
tumors are typically P53 driven and genetically instable [4], the chemotherapy response 
varies significantly among the patients. Therefore, a large number of clinical trials have 
been performed to develop and test the efficacy of new biologically targeted agents, drugs 
and/or chemotherapeutic procedures. However, one of the major challenges in these 
clinical trials is the limited ability to accurately categorize patients to find a certain group 
of patients which is more likely to respond to target treatment. In addition, most of the 
chemotherapy drugs have significant side effects and high costs. As a result, there is a 
clinically imperative need for developing an early stage prognostic assessment method to 
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accurately categorize the patients into groups that are likely or not to benefit from the 
new therapies. 
 
Figure 1: Five-year survival rate of epithelial ovarian cancer patients according to 
National Cancer Institute, SEER Data Base for the patients diagnosed from 1995 to 2007 
[3] 
 
Evaluating early response to chemotherapy drugs 
Extensive researches have been conducted to develop novel clinical markers for 
prognostic assessment of tumor response to chemotherapy, which can be classified into 
two subgroups: genetic biomarkers and radiographic imaging. In the recent years, many 
genetic biomarkers have been discovered and investigated [4-6] to select optimal 
treatment methods [7-9]. However due to the complexity and heterogeneity of ovarian 
cancer, no existing biomarkers are able to accurately select treatment options, predict 
clinical benefit, and determine drug resistance to date. This could be attributed by the 
facts that the current biomarkers are (1) applicable only to a certain group of patients [8-
3 
 
10], (2) high costs [11-12] and (3) lower specificity [13-15]. Hence, radiographic imaging 
analyses are critically important to assess the prognostic response of ovarian cancer 
treatment [5-6].  
 
Radiographic imaging  
Current imaging modalities in treating ovarian cancer include ultrasound, 
perfusion X-ray computed tomography (CT), magnetic resonance imaging (MRI) and 
Positron emission tomography (PET). Due to several benefits like wider availability, 
rapid acquisition of images, a wealth of clear and specific information, high diagnostic 
performance, and low operating cost, perfusion X-ray CT is considered to be the most 
popular technique currently used for prognostic assessment of ovarian cancer in clinical 
practice [7]. 
 
RECIST guidelines  
Response Evaluation Criteria in Solid Tumors (RECIST) is the current clinical 
standard to assess patients’ response to treatment [8-9] (i.e. tumors in cancer patients 
increase, stabilize or decrease). RECIST evaluation includes following steps: (1). 
Identify, record and measure all measurable lesions up to 2 per organ and a maximum of 
5 in total for all organs. The target lesions are selected based on their size/ longest 
diameter (LD) and their suitability for further measurements. (2). Compute the sum of the 
LD’s of all the target lesions for response assessment. The assessment can be classified 
into four groups: Complete Response (CR): Disappearance of all target lesions; Partial 
Response (PR): Decrease of at least 30% in the sum of LD’s of all the target lesions; 
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Progressive Disease (PD): Increase of at least 20% in the sum of LD’s of all the target 
lesions; Stable Disease (SD): Insignificant increase or decrease in the sum of LD’s of 
target lesions to be classified as either PD or PR respectively. 
 
Radiologist assessment  
In order to assess the patients’ response to new chemotherapy drugs or procedures, 
radiographic perfusion CT examinations were performed on each patient. This study 
includes one set of CT scan images taken pre-therapy and a multiple sets of CT scans 
taken during the period of post therapy. In order to assess and/or categorize patients’ 
response, radiologists will examine and mark up to 5 metastatic tumors from the pre- and 
post- treatment CT images, using RECIST guidelines. However, these results are based 
on one-dimensional size and don’t take changes in tumor volume [10] to consideration 
often leading to a low association between radiologist results and clinical outcome [11]. 
 
Computer Aided Detection (CAD) scheme 
In order to improve the early prognostic assessment of patients’ response and 
assist the radiologist in making optimal treatment decisions for ovarian cancer patients, a 
CAD scheme was developed to more accurately assess the tumor response to 
chemotherapy, using pre- and post- treatment CT images. The scheme firstly segments 
tumors marked by radiologist and then computes quantitative image features to detect and 
quantify tumor volume, shape, and density heterogeneity. The individual and combined 
features are finally used to predict 6-month progression free survival (PFS) of the patients, 
which is both recommended and approved criterion by Food and Drug Administration 
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(FDA) of the United States and European Medicines Agency (EMA) [12]. The overall 
objective of this study is to examine 1) whether quantitative image features computed 
from pre-therapy CT images offer information to predict patient response prior to 
chemotherapy and 2) whether quantitative image features computed from both pre- and 
post- therapy CT images offer significantly higher prediction capabilities to predict 
ovarian cancer patients response to chemotherapy than using traditional RECIST criteria. 
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Chapter 2: Materials 
Image dataset 
Under institutional review board (IRB) approved protocol, we retrospectively 
collected a dataset consisting of de-identified CT images acquired from 91 ovarian cancer 
patients. Each patient was diagnosed with recurrent, high-grade (serous, endometrioid or 
mixed) ovarian/ peritoneal /tubal carcinoma and underwent a clinical trial. The clinical 
trials involved 32 different new therapeutic drugs, each patient was given a mixture of 
1/2/3 drugs which depends on her condition and doctor’s treatment decision. Two sets of 
CT scans: pre-treatment and 4-6 weeks post-treatment were acquired for each patient. 
These CT images were obtained based on a pre-established CT scanning protocol in our 
medical center using either a 64-row detector CT machine (Light Speed VCT, GE 
Healthcare, Milwaukee, WI, USA) or a 16-row detector CT machine (Discovery 600, GE 
Healthcare). The X-ray power was operated at 120 kVp and 100-600mAs, depending 
upon the patient body size. A 100cc of contrast agent was injected into patient’s body at 
a rate of 2-3cc/sec before CT examinations for better visualization of the tumor. 
For each case, radiologist tracked the metastatic tumors in both pre- and post-
treatment CT image, and the tumor size changes were estimated based on RECIST 
criteria. Since our study is retrospective, the 6 month PFS were also collected in the 
dataset for the performance assessment. In this dataset, 52 patients remained 6-month 
PFS (CR, PR, SD), while 39 did not maintain 6-month PFS to the treatment with signs of 
progressive disease (PD). Table 1 summarizes the detailed information about both the 
classes of patients 
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Table 1: Detailed information about patients separated by PFS 
 
PFS "Yes" PFS "No" 
Number of patients 52 39 
Patient average age 66 ± 8 67 ± 9 
Number of metastatic 
tumors 
101 96 
Average tumor diameter  
(before therapy) 
27 mm 24mm 
 * The chemotherapy agent given varies among patients 
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Chapter 3: Quantitative image features analysis 
Segmentation methods 
In order to segment the tumors effectively and efficiently, we developed a 
segmentation scheme consisting of 8 different segmentation algorithms. This 
segmentation scheme can be categorized in to 3 sub-groups: 1) region growing methods, 
2) canny operator based methods and 3) partial differential equation based methods. 
Figure 2 illustrates the flowchart for these three types of methods. 
 
                                  (a)                                                        (b) 
 
 (c) 
Figure 2: Flow chart of (a) region growing, (b) canny operator and (c) partial differential 
equation based segmentation algorithms 
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Region growing methods 
This sub-group consists of two segmentation algorithms: connected and 
neighborhood region growing segmentation. Connected region growing is a modified 
form of regular region growing algorithm. For the connected region growing method, we 
initially select a seed point within the tumor and then evaluate whether its neighboring 
pixels are part of the tumor or not. If the intensity difference between neighbor pixel and 
the initial seed point is below the pre-determined threshold value, the neighbor pixel is 
considered as a part of tumor. This process is repeated for all the connected pixels until 
no neighboring pixel can satisfy the threshold condition. Neighborhood region growing 
is similar to the connected region growing method, and the only difference is that the 
pixel will be considered as part of the tumor if all its neighbors satisfy the intensity 
difference threshold. 
Canny operator methods 
This sub-group consists of two algorithms: Canny boundary extraction and multi-
scale canny methods. Canny boundary extraction method includes three steps. First, A 
Gaussian filter is used to suppress the noise in the image. Next, a gradient intensity image 
is computed, for which hysteresis threshold is applied to optimize the edge detection. For 
this method, two thresholds (high and low thresholds) are used on the gradient intensity 
image, where high threshold filters the noise and maps the genuine edges in the image 
(T1), and low threshold is applied to track back the faint edges in T1 and make a 
continuous boundary image (T2). Finally, dilation is applied from the initial set seed point 
in all the direction until it reaches the traced continuous boundary to extract the tumor. 
Multi-scale canny method is a modified form of canny edge detection algorithm which 
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uses down sampled image with different scales. In canny edge detection, the resulting 
image can be considered as the convolution between the original image F and first 
derivative of the Gaussian kernel θ: 
 
𝜕𝐹(𝑥,𝑦)⊗𝜃(𝑥,𝑦)
𝜕𝑥
= 𝐹(𝑥, 𝑦) ⊗
𝜕𝜃(𝑥,𝑦)
𝜕𝑥
= 𝐹(𝑥, 𝑦) ⊗ 𝜓1(𝑥, 𝑦)  (1) 
 
𝜕𝐹(𝑥,𝑦)⊗𝜃(𝑥,𝑦)
𝜕𝑦
= 𝐹(𝑥, 𝑦) ⊗
𝜕𝜃(𝑥,𝑦)
𝜕𝑦
= 𝐹(𝑥, 𝑦) ⊗ 𝜓2(𝑥, 𝑦)  (2) 
In case of multi-scale canny, we use dilated Gaussian kernel as follows: 
 𝜓
2𝑗
1 =
1
2𝑗
𝜓1 (
𝑥
2𝑗
,
𝑦
2𝑗
)  (3) 
  𝜓
2𝑗
2 =
1
2𝑗
𝜓2 (
𝑥
2𝑗
,
𝑦
2𝑗
)  (4) 
Thus we compute the dilated derivative image at different scales: 
 𝐷
2𝑗
1 (
𝜕𝐹(𝑥,𝑦)⊗𝜃(𝑥,𝑦)
𝜕𝑥
) = 𝐹(𝑥, 𝑦) ⊗ 𝜓
2𝑗
1   (5) 
 𝐷2𝑗
2 (
𝜕𝐹(𝑥,𝑦)⊗𝜃(𝑥,𝑦)
𝜕𝑦
) = 𝐹(𝑥, 𝑦) ⊗ 𝜓
2𝑗
2   (6) 
In this study, the multi-scale edge detection is accomplished by applying the 
canny operator on the down sampled image with different scales. Given that most tumors 
are small, the scale number j is set to be 1 in this experiment. The multi-scale canny edge 
detecting operation is implemented by performing the canny operator on the down 
sampled images. After the operation, the extracted boundary is up sampled to the original 
scale. 
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Partial differential equation methods 
The algorithms in this group are based on level set segmentation and consist of 
four algorithms: Fast marching, shape detection, geometric active contour and threshold 
level set methods. For level set methods, the boundary function 𝑓(𝑥, 𝑦) is defined as a 
curve when setting the three dimensional surface ψ to be a constant number 𝐶: ψ(𝑥, 𝑦) =
𝐶. In most cases, the three dimensional initial surface is a paraboloid and its boundary 
curve is a circle. Next, the surface propagates based on the gradient values of the target 
image and its boundary changes accordingly. Surface propagation can be described using 
partial differential equation as below: 
 
𝜕𝜓
𝜕𝑡
+ 𝐹|𝛻𝜓| = 0  (7) 
 
𝜕𝜓
𝜕𝑡
= −𝐹𝐴|𝛻𝜓| − 𝐹𝐺|𝛻𝜓| − 𝐹𝑘𝑘|𝛻𝜓|  (8) 
Where 𝐹𝐴 is the advection speed given by the user, 𝐹𝐺  is the local geometric speed 
term as follows: 
 𝐹𝐺 = −
𝐹𝐴
(𝑀1−𝑀2)
{|𝛻𝐺𝜎 ∗ 𝐼(𝑥, 𝑦)| − 𝑀2}  (9) 
Where 𝑀1, 𝑀2 are the maximum and minimum of image gradients, 𝛻𝐺𝜎 is the 
gradient Gaussian kernel, I(x, y) is the image. Accordingly, the total speed of the surface 
propagation will be slow at the high gradient image area and high at the low gradient area. 
Given that the image gradient will be maximized at the tumor boundary, the surface will 
stop or move very slowly at the boundary. 
In fast marching, the image is initially pre-processed using three steps. First, an 
anisotropic filter is applied to smooth the image. Next, gradient image is computed. After 
that, the gradient image is passed to a sigmoid filter. Using the gradient image, the local 
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propagation speed  𝐹𝐺  is estimated by formula (9). The surface propagation is finally 
determined by 𝐹𝐴, and  𝐹𝐺: 
 
𝜕𝜓
𝜕𝑡
= −𝐹𝐴|𝛻𝜓| − 𝐹𝐺|𝛻𝜓|  (10) 
In shape detection, the surface propagation uses all the three terms including mean 
curvature term (𝐹𝑘). This term improves the boundary propagation by removing the noisy 
area in the target image. 
 
𝜕𝜓
𝜕𝑡
= −𝐹𝐴|𝛻𝜓| − 𝐹𝐺|𝛻𝜓| − 𝐹𝑘𝑘|𝛻𝜓|  (11) 
Where curvature term 𝐹𝑘 is estimated as follows: 
 𝑘 = −
𝜓𝑥𝑥𝜓𝑦
2 −2𝜓𝑥𝜓𝑥𝜓𝑥𝑦+𝜓𝑦𝑦𝜓𝑥
2
(𝜓𝑥
2+𝜓𝑦
2)3/2
  (12) 
In Geometric active contour, a second advection term is added to the surface 
propagation which is able to attract the computed contour to the target tumor boundary. 
 
𝜕𝜓
𝜕𝑡
= −𝐹𝐴|𝛻𝜓| − 𝛼𝑔(𝐼)|𝛻𝜓| − 𝐹𝐺|𝛻𝜓| − 𝐹𝑘𝑘|𝛻𝜓|  (13) 
For the last algorithm, threshold level set is a combination of both region growing 
and level set algorithms. A pre-determined threshold interval [LT, UT] is used to identify 
the tumor, while the smoothness of the propagation surface stops the leakage that usually 
happens in region growing algorithms. 
The sample segmentation images of all the above discussed eight segmentation 
techniques are shown in the Figure 3. 
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 (a)                                (b)                              (c)                               (d)  
                        
              (e)                                (f)                              (g)                               (h)  
Figure 3: Segmentation samples of (a) connected (b) neighborhood (c) canny (d) multi-
canny (e) fast marching (f) shape detection (g) geometric (h) threshold segmentation 
algorithms 
 
Shape/volume based features 
This group includes 10 shape and/or volume based features (F1-F10) [14-17]. 
These features estimate tumor characteristics including shape, volume, and related 
geometric distortions.  
1. Convexity: It describes the smoothness of edges of the tumor, which can be 
calculated as follows: 
 𝑐𝑜𝑛𝑣𝑒𝑥𝑖𝑡𝑦 =   
𝑇𝑢𝑚𝑜𝑟 𝑟𝑒𝑔𝑖𝑜𝑛 𝑎𝑟𝑒𝑎
𝐶𝑜𝑛𝑣𝑒𝑥 𝑟𝑒𝑔𝑖𝑜𝑛 𝑎𝑟𝑒𝑎
  (14) 
2. Tumor volume: This is the total volume of all the tumor voxels. 
3. Max radius: we computed all the possible radii between the center and all tumor 
surface pixels. Then the maximum of radii is considered as the max radius. 
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4. STD RL: It is the ratio of standard deviation and average of all the radii between 
center and tumor surface pixels. 
 
𝑆𝑇𝐷 𝑅𝐿 =
√∑ (𝐼𝑖−𝑅 𝑖)
2𝑁
𝑖=1
𝑁−1
1
𝑁
∑ 𝑅 𝑖
𝑁
𝑖=1
=  
𝑆𝑇𝐷 𝑜𝑓 𝑟𝑎𝑑𝑖𝑖
𝑚𝑒𝑎𝑛 𝑜𝑓 𝑟𝑎𝑑𝑖𝑖
  
(15) 
5. Surface area: In order to simplify the computation, the tumor is approximated by 
generalized cylinder. Accordingly, the surface area of the generalized cylinder is 
used as an estimation of the tumor surface area.  
6. Compactness1:  
 𝑐𝑜𝑚𝑝𝑎𝑐𝑡𝑛𝑒𝑠𝑠1 =  
𝑉
√  𝜋𝐴
2
3
  (16) 
7. Compactness2: 
 𝑐𝑜𝑚𝑝𝑎𝑐𝑡𝑛𝑒𝑠𝑠2 =  
36 𝜋𝑉2
𝐴3
  (17) 
8. Spherical disproportion: It measures the difference between the tumor surface 
and a sphere with equivalent radius: 
 𝑠𝑝ℎ𝑒𝑟𝑖𝑐𝑎𝑙 𝑑𝑖𝑠𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 =  
𝐴
4𝜋𝑅2
  (18) 
9. Sphericity: This feature is a measurement of the shape distortion of the tumor 
when comparing with the sphere, which is computed as follows:  
 𝑆𝑝ℎ𝑒𝑟𝑖𝑐𝑖𝑡𝑦 =  
𝜋
1
3(6𝑉)
2
3 
𝐴
  (19) 
10. Surface area to tumor volume: It is the ratio of surface area to the tumor volume. 
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Density features 
These features are computed based on pixel intensities within the tumor and/or 
surrounding boundary pixels and describe their distribution [18]. This subgroup consists 
of 21 features (F11-F31), among which (F11-F15) are computed based on the 2D central 
slice and the rest of them are computed based on 3D tumors which are discussed below: 
1. ISO-intensity: The feature computes the density of all the outer ring (boundary) 
pixels for which the intensity is higher than the threshold determined by the pixels 
inside the tumor. (where,10th percentile intensity of pixel values inside the tumor 
is the threshold) 
2. Fluctuation mean: The fluctuation is defined as the maximum absolute 
difference between the target (Central) pixel and all the neighbor pixels within its 
5×5 neighborhood. Thus fluctuation mean is the average fluctuation value for all 
the tumor pixels. 
3. Fluctuation standard deviation: This feature is the standard deviation of 
fluctuation value of all the tumor pixels. 
4. Gradient Mean: It is defined as the average gradient value of all the tumor 
boundary pixels.  
5. Gradient standard deviation: This feature is the standard deviation of gradient 
value of all boundary pixels. 
6. Density: This feature computes the average intensity of all the pixel values within 
the tumor. 
7. Standard deviation of density: It computes the standard deviation of all the pixel 
values within the tumor. 
16 
 
8. Mean contrast: For this feature, we initially compute an inner ring within the 
tumor and an outer ring surrounding the tumor then, the intensity ratio of the inner 
ring to surrounding outer ring is computed as follows: 
 𝑚𝑒𝑎𝑛 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 =  
𝑚𝑒𝑎𝑛 𝑜𝑓 𝑖𝑛𝑛𝑒𝑟 𝑟𝑖𝑛𝑔 𝑡𝑢𝑚𝑜𝑟 𝑝𝑖𝑥𝑒𝑙𝑠 (𝐼𝑖𝑛𝑛𝑒𝑟)
𝑚𝑒𝑎𝑛 𝑜𝑓 𝑜𝑢𝑡𝑒𝑟 𝑟𝑖𝑛𝑔 𝑏𝑜𝑢𝑛𝑑𝑎𝑟𝑦 𝑝𝑖𝑥𝑒𝑙𝑠 (𝐼𝑜𝑢𝑡𝑒𝑟)
  (20) 
9. Contrast: It is the difference between the mean of inner ring tumor pixels and the 
mean of surrounding outer ring boundary pixels.  
 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 =  𝐼𝑖𝑛𝑛𝑒𝑟 − 𝐼𝑜𝑢𝑡𝑒𝑟  (21) 
10. Skewness: Skewness measures the asymmetry of the probability distribution 
curve of all the tumor pixel values about its mean. 
 𝑠𝑘𝑒𝑤𝑛𝑒𝑠𝑠 =  √𝑁 ∗
∑ (𝑰𝒊−𝑰)
𝟑𝑵
𝒊=𝟏
∑ (𝑰𝒊−𝑰)
𝟑
𝟐𝑵
𝒊=𝟏
  (22) 
11. Kurtosis: Kurtosis measures the "tailed-ness" of the tumor density distribution 
when comparing to the standard normal distribution:  
 𝑘𝑢𝑟𝑡𝑜𝑠𝑖𝑠 =  𝑁 ∗
∑ (𝑰𝒊−𝑰)
𝟒𝑵
𝒊=𝟏
(∑ (𝑰𝒊−𝑰)
𝟐
) 𝑵𝒊=𝟏
𝟐  (23) 
12. STD ratio: It is defined as the ratio of STD of tumor intensity to the boundary 
intensity.  
13. Energy: It is a sum of the squared tumor pixel values. 
 𝐸𝑛𝑒𝑟𝑔𝑦 =  ∑ 𝐼𝑖
2𝑁
𝑖=1    (24) 
14. Entropy: This feature describes the randomness/ uncertainty in an image. 
 𝐸𝑛𝑡𝑟𝑜𝑝𝑦 =  ∑ 𝑃𝑖 𝑙𝑜𝑔2 𝑃𝑖
𝑁𝑙
𝑖=1   (25) 
Where 𝑃 is first order histogram of tumor pixels with 𝑁𝑙 discrete intensity levels. 
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15. Max: It is the maximum value of all the tumor pixels 
16. Mean absolute deviation: It is defined as the mean absolute deviation between 
the tumor pixel value and the average tumor intensity:  
 𝑀𝑒𝑎𝑛 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 =  
1
𝑁
∑ |𝐼𝑖 − 𝐼|
𝑁
𝑖=1   (26) 
17. Median: It is the median value of all the tumor pixels. 
18. Min: It is the minimum value of all the tumor pixels. 
19. Range: It measures difference between the maximum and a minimum value of all 
tumor pixels. 
20. RMS: it is the root mean square value of tumor pixels. 
21. Uniformity: This feature is a measure of histogram randomness and can be 
computed as follows: 
 𝑈𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =  ∑ 𝑃𝑖
2𝑁𝑙
𝑖=1   (27) 
 
Texture based features 
These features are computed using the gray level run length (GLRL). Gray level 
run is the number of consecutive elements with the same gray level in a certain direction 
(i.e. 0°, 45°, 90°, and 135°), while the run length is the number of the gray level run. 
The run length provides meaningful texture information for tumor classification 
[19-20]. In our study, we estimated a total of 11 texture features [21-23] and are as 
follows: 
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1. Short Run Emphasis (SRE) 
 𝑆𝑅𝐸 =  
1
𝑛𝑟
∑ ∑
𝑝(𝑖,𝑗)
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1 =  
1
𝑛𝑟
∑
𝑝𝑟(𝑗)
𝑗2
𝑁
𝑗=1   (28) 
2. Long Run Emphasis (LRE) 
 𝐿𝑅𝐸 =
1
𝑛𝑟
∑ ∑ 𝑝(𝑖, 𝑗). 𝑗2𝑁𝑗=1
𝑀
𝑖=1 =  
1
𝑛𝑟
∑ 𝑝𝑟(𝑗). 𝑗
2𝑁
𝑗=1   (29) 
3. Gray-Level Non-uniformity (GLN) 
     𝐺𝐿𝑁 =  
1
𝑛𝑟
∑ (∑ 𝑝(𝑖, 𝑗)𝑁𝑗=1 )
2𝑀
𝑖=1 =
1
𝑛𝑟
∑ 𝑝𝑔(𝑖)
2𝑀
𝑖=1   (30) 
4. Run-Length Non-uniformity (RLN) 
 𝑅𝐿𝑁 =  
1
𝑛𝑟
∑ (∑ 𝑝(𝑖, 𝑗)𝑀𝑖=1 )
2𝑁
𝑗=1 =
1
𝑛𝑟
∑ 𝑝𝑟(𝑖)
2𝑁
𝑗=1   (31) 
5. Run Percentage (RP) 
 𝑅𝑃 =  
𝑛𝑟
𝑛𝑝
  (32) 
6. Low Gray-Level Run Emphasis (LGRE) 
 𝐿𝐺𝑅𝐸 =  
1
𝑛𝑟
∑ ∑
𝑝(𝑖,𝑗)
𝑖2
= 𝑁𝑗=1
𝑀
𝑖=1
1
𝑛𝑟
∑
𝑝𝑔(𝑖)
𝑖2
𝑀
𝑖=1   (33) 
7. High Gray-Level Run Emphasis (HGRE) 
 𝐻𝐺𝑅𝐸 =  
1
𝑛𝑟
∑ ∑ 𝑝(𝑖, 𝑗). 𝑖2𝑁𝑗=1
𝑀
𝑖=1 =
1
𝑛𝑟
∑ 𝑝𝑔(𝑖). 𝑖
2𝑀
𝑖=1   (34) 
8. Short Run Low Gray-Level Emphasis (SRLGE) 
 𝑆𝑅𝐿𝐺𝐸 =  
1
𝑛𝑟
∑ ∑
𝑝(𝑖,𝑗)
𝑖2 .𝑗2
𝑁
𝑗=1
𝑀
𝑖=1   (35) 
9. Short Run High Gray-Level Emphasis (SRHGE) 
 𝑆𝑅𝐻𝐺𝐸 =  
1
𝑛𝑟
∑ ∑
𝑝(𝑖,𝑗).𝑖2
𝑗2
𝑁
𝑗=1
𝑀
𝑖=1   (36) 
10. Long Run Low Gray-Level Emphasis (LRLGE) 
 𝐿𝑅𝐿𝐺𝐸 =  
1
𝑛𝑟
∑ ∑
𝑝(𝑖,𝑗).𝑗2
𝑖2
𝑁
𝑗=1
𝑀
𝑖=1   (37) 
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11. Long Run High Gray-Level Emphasis (LRHGE) 
 𝐿𝑅𝐻𝐺𝐸 =  
1
𝑛𝑟
∑ ∑ 𝑝(𝑖, 𝑗). 𝑖2. 𝑗2𝑁𝑗=1
𝑀
𝑖=1   (38) 
In these formulas, P is a GLRL matrix, in which P (i, j) is the number of runs for 
gray level i and length j. 𝑛𝑟  is total number of runs, and 𝑛𝑝 is the number of distinctive 
elements in the GLRL matrix P. 
Given that the above 11 GLRL features can be estimated in four different 
directions (i.e. 0°, 45°, 90° and 135°), thus we finally have 44 GLRL features. (F32-F75 
GLRL features in four directions). 
 
Wavelet features 
In this study, a two-dimensional wavelet transform ("Coiflet 1" filter) was applied 
on each image [18], which decomposes the original image (I) into four components: ILL, 
ILH, IHL, and I HH, where L and H denotes the low and high pass filters respectively. For 
example, IHL is obtained by applying high-pass filter along the x-direction and low pass 
filter along y-direction on original CT image (I). Mathematically, it can be described as 
follows: 
 𝐼𝐻𝐿(𝑖, 𝑗) =  ∑ ∑ 𝐻(𝑝)𝐿(𝑞)𝐼(𝑖 + 𝑝, 𝑗 + 𝑞)
𝑁𝐿
𝑞=1
𝑁𝐻
𝑝=1   (39) 
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Figure 4: Wavelet decomposition of target CT slice using wavelet transforms (one-level 
and un-decimated two-dimensional wavelet transforms using "Coiflet 1" filter) 
 
Accordingly, for each component, we estimated the same density features as 
described above. All the features are summarized in Table 2. 
Table 2: Summary of all the 159 features separated by their feature class 
Feature 
class 
Feature 
number 
Feature description 
 
Shape 1-10 convexity, Tumor volume, maximum radius, STD RL , surface area, 
compactness feature 1, compactness feature 2, spherical 
disproportion, Sphericity, ratio of surface area to Tumor volume 
Density 11-31 ISO-intensity, fluctuation mean, fluctuation STD, gradient mean, 
gradient STD, Density, density STD, mean contrast, contrast, 
skewness, kurtosis, STD ratio of tumor to boundary, energy, entropy, 
maximum intensity, mean absolute deviation, median, minimum, 
range, rms, uniformity 
 
Texture 32-75 11 gray level run length based features extracted in four directions 
(0°, 45°, 90°, and 135°)  
Wavelet 76-159 Apply the density features on the four wavelet components 
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For each case, we computed these 159 features on both pre-treatment (Fi
Pre) and 
4-6 week follow-up (Fi
Post) CT image sets. Then, the tumor feature differences ∆Fi =
 Fi
Post −  Fi
Pre were also computed. After that, feature sets Fi
Pre, ∆Fi were normalized 
within the range between μ + 2σ and μ − 2σ, where μ and σ denote the mean and 
standard deviation of the feature values respectively. In accordance with the RECIST 
guidelines, 1 to 5 tumors were tracked and studied by radiologists for different cases. In 
this study, the average feature computed from M tumors (1 ≤ M ≤ 5) corresponding to 
the same case was also computed and used to represent the final case-based feature value. 
We used the case-based features to assess their association to the 6-month PFS of the 
patient. 
After building two initial feature pools containing Fi
Pre and ∆Fi = Fi
Post − Fi
Pre, 
we firstly assessed the performance of each feature, using receiver operating 
characteristic (ROC) curve[21-22]. Then we sorted features based the area under the 
curve (AUC) values and top 20 features are selected in both feature pools, to investigate 
whether using feature difference ∆Fi = Fi
Post − Fi
Pre could yield significantly high 
performance than using the features computed from pre-therapy CT images only. Next, 
an equal-weighted Fusion model was built to combine the optimal feature cluster and 
generate a new combined feature marker to predict the 6-month progression free survival 
(PFS). We also used the ROC analysis method to assess the predicting performance of 
the combined marker. Finally, we built three confusion matrices using the prediction 
results generated by two fusion image markers and RECIST criteria used by radiologists 
in current clinical practice. The predicting accuracy of our new quantitative image 
markers were compared with the conventional RECIST method. 
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Chapter 4: Results 
Tumor segmentation results 
A number of 138 tumors are used to assess the performance of these segmenting 
algorithms. All of these tumors are selected and tracked from the advanced ovarian cancer 
patients with recurrent metastatic tumors. Figure 3 illustrates some typical segmenting 
examples of the eight methods, which demonstrated that these methods are effective for 
the tumor segmentation of the ovarian cancer cases. However, given that the metastatic 
tumors are highly sophisticated, none of the above eight approaches are able to effectively 
segment all the tumors. As indicated in Table 3, the PDE based methods are achieved a 
better performance than the region growing and Canny boundary operator methods, for 
which the fast marching, geometric active contour, and threshold level set yielded a 
number of 106, 104, and 107 satisfied segmenting results. In addition, although each 
single method is not able to segment all of these tumors, each of the tested tumors can be 
successfully segmented by at least one of the eight methods without the manual boundary 
correction. 
Table 3: Summary of the eight segmenting result of the 138 metastatic tumors for the 
advanced stage ovarian cancer patients 
Segmenting 
methods 
Region 
growing 
Neighborhood 
region growing 
Canny operator Multi-scale 
canny 
Unsatisfied 78 102 76 109 
Satisfied 60 36 62 29 
Segmenting 
methods 
Fast 
marching 
Geometric 
active contour 
Shape 
detection 
Threshold 
level set 
Unsatisfied 32 34 48 31 
Satisfied 106 104 90 107 
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          (a)       (b)                         (c)                        (d)                        (e)           
Figure 5: An aortic tumor segmented by our hybrid segmenting scheme from the (a) 2nd 
upper adjacent slice (b) 1st upper adjacent slice (c) central slice selected by the radiologist 
(d) 1st lower adjacent slice (e) 2nd lower adjacent slice 
 
In order to segment the 3D tumor from the multiple CT slices, the professional 
radiologist will first mark one central slice containing the tumor, which was segmented 
by one of the developed algorithms. Once the tumor region and boundary contour are 
segmented on this center slice, the result provides a reference to guide the segmentation 
of the tumor regions depicting on the two adjacent CT image slices. The scheme will keep 
segmenting the tumors on the adjacent slices until the tumor disappears. Figure 5 shows 
an example of 3-D aortic tumor segmented from a series of adjacent CT image slices. The 
tumor depicted on Figure 5 (c) was first segmented from the target slice marked by the 
radiologist, which has the largest 2-D area. Figure 5 (d) and (e) indicate that the tumor 
significantly decreases and disappear on the first and second lower adjacent slices, 
respectively. The similar results can also be revealed on the upper adjacent slices, as 
shown in Figure 5 (a) and (b). 
 
Quantitative image feature analysis results 
Table4, Table 5 summarizes two sets of 20 best performed image features computed from 
pre-therapy CT image only and two CT scans acquired pre- and pre-post therapy. The 
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pre-therapy set consists of five tumor density features (Skewness, Uniformity, Entropy, 
kurtosis, and STD), thirteen wavelet features (Contrast-LH, Contrast-HL, Skewness-HH, 
Density std Ratio-HL, Kurtosis-HL, Mean contrast-LH, Density std Ratio-HH, 
Skewness-LH, Range-HL, Density-LH, Mean contrast-HL, Minimum density-LH, and 
Kurtosis-LL), and two tumor shape features (Sphericity and Compactness-2). AUC 
values of these 20 features range from 0.5692 to 0.6842. The best performed feature is 
Skewness with an AUC value of 0.6842±0.0557. Similarly, another set based on the 
image feature difference between the pre- and post-therapy has nine tumor density 
features (Energy, Median, Rms, Average density, Maximum density, Density range, 
Fluctuation std, std-RL, and Entropy), eight wavelet features (Fluctuation std-LL, 
Entropy-HL, Energy-HH, Entropy-LL, Energy-HL, Maximum density-HH, Maximum 
density-HL, and Gradient mean-HL), and three tumor shape features (Compactness-1, 
Tumor volume, and Surface area). AUC values of using these 20 features ranged from 
0.6511 to 0.7705, among which the feature of Compactness-1 yielded the highest AUC 
value of 0.7705±0.0495. 
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Table 4: Summary of top 20 features obtained using pretreatment CT images 
Feature AUC ± STD Feature AUC ± STD 
Skewness 0.6842 ± 0.0557 Mean contrast-LH 0.5960 ± 0.0601 
Contrast-LH 0.6521 ± 0.0592 Kurtosis 0.5923 ± 0.060 
Contrast-HL 0.6426 ± 0.0576 Density std Ratio-HH 0.5907 ± 0.0614 
Uniformity 0.6367 ± 0.0579 Skewness-LH 0.5877 ± 0.0597 
Skewness-HH 0.6225 ± 0.0586 Range-HL 0.583 ± 0.0611 
Sphericity 0.6209 ± 0.0579 Density-LH 0.578 ± 0.0609 
Entropy 0.6192 ± 0.0589 Mean contrast-HL 0.5774 ± 0.0599 
Density std Ratio-HL 0.6178 ± 0.0581 Minimum density-LH 0.5734 ± 0.0617 
Kurtosis-HL 0.6149 ± 0.0587 Kurtosis-LL 0.5704 ± 0.0608 
Compactness2 0.6022 ± 0.0585 STD of density 0.5692 ± 0.0613 
 
Table 5: Summary of top 20 features obtained using both pre and posttreatment CT 
images 
Feature AUC ± STD Feature AUC ± STD 
Compactness 1 0.7705 ± 0.0495 Density range 0.677 ± 0.0558 
Volume 0.7547 ± 0.0512 Energy-HH 0.6696 ± 0.0567 
Surface area 0.7389 ± 0.0523 Entropy-LL 0.6688 ± 0.0555 
Fluctuation std-LL 0.7108 ± 0.0535 Energy-HL 0.6671 ± 0.0597 
Energy 0.7066 ± 0.0548 Maximum density-HH 0.6629 ± 0.058 
Median 0.6949 ± 0.0542 Fluctuation std 0.6616 ± 0.056 
Entropy-HL 0.6865 ± 0.0545 Maximum density-HL 0.6603 ± 0.0582 
Rms 0.685 ± 0.0549 Gradient mean-HL 0.6583 ± 0.0565 
Density  0.6835 ± 0.0549 Std-RL 0.6532 ± 0.0563 
Maximum density 0.6815 ± 0.0555 Entropy 0.6511 ± 0.0566 
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The selected optimal clusters consisting of 4 and 9 features from two feature sets 
of (1) using pretreatment CT images only (𝐹𝑖
𝑃𝑟𝑒) and (2) using both pre- and post-
treatment CT images (∆𝐹𝑖) respectively. These optimal clusters were evaluated using 
ROC curve. As indicated in Figure 6Figure 7, the AUC values of final fusion markers are 
0.8103 ±  0.0447 and 0.8292 ± 0.0431 for optimal feature cluster sets (𝐹𝑖
𝑃𝑟𝑒) 
and(∆𝐹𝑖) respectively. The predicting powers of the fused markers are significantly 
higher when comparing to the AUC values of single features in the initial individual 
feature sets. At a specificity of 0.6, the sensitivity values are 0.8241 and 0.8735 for the 
final pre-treatment and the pre-post treatment fusion markers respectively. 
 
Figure 6: ROC curves of the best individual feature and the final fusion image marker 
for pre-treatment features 
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Figure 7: ROC curves of the best individual feature and the final fusion image marker 
for pre-posttreatment features 
 
Table 6,Table 7, and Table 8 shows the confusion matrices obtained using two 
fusion markers and conventional RECIST criteria respectively. The pre-treatment marker 
predicts 46 cases as responsive cases, among which 36 cases are clinically responsive to 
the therapy. Similarly, this marker predicts 45 cases as non-responsive cases, and 29 of 
them are clinical non-responders. Thus the pre-treatment marker yields a positive 
predictive value (PPV) of 78.26% and a negative predictive value (NPV) of 64.44%. The 
overall prediction accuracy of this pre-fusion marker is achieved as 71.43%. For the pre-
post treatment marker, 60 and 31 cases are predicted as responsive and non-responsive 
cases, among which 47 and 26 cases are clinical responders or non-responders. Therefore 
the PPV and NPV are 78.33% and 83.87%, respectively. As a result, an overall prediction 
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accuracy of 80.22% was obtained for the pre-post fusion marker. As a comparison, Table 
8 summarizes the confusion matrix of the conventional RECIST method, in which CR, 
PR, and SD are considered as responsive to treatment by maintaining 6-month PFS and 
PD as non-responsive to treatment. The overall prediction accuracy using RECIST 
criteria is 74% 
Table 6: A confusion matrix predicting 6-month PFS when fusing features obtained from 
pre-treatment CT images 
                    6-month PFS 
Prediction                
Yes No 
Yes 36 10 
No 16 29 
 
Table 7: A confusion matrix predicting 6-month PFS when fusing features obtained from 
both pre- and post-treatment CT images 
                    6-month PFS 
Prediction                
Yes No 
Yes 47 13 
No 5 26 
 
Table 8: A confusion matrix predicting 6-month PFS when using RECIST criteria 
                    6-month PFS 
Prediction                
Yes No 
Yes 52 23 
No 0 16 
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Chapter 5: Discussion 
CT is the most widely used imaging modality for assessing the efficacy of 
chemotherapy drugs in treating ovarian cancer patients. Currently, most of the clinical 
evaluations are based on RECIST criteria which use one-dimensional tumor diameter 
change to categorize patients’ response to chemotherapy. However, the previous studies 
have proved that diameter change cannot be sole measure for optimal assessment. For 
example, 1) when using bevacizumab-based therapy in clinical trials to treat recurrent 
ovarian cancer, RECIST based assessment categorized 21% as responsive when there 
were actually 40% patients who remained 6-moth PFS [26]. 2) When using immune-
stimulatory agents like CTLA4 for therapy, some tumors might have an initial increase 
in tumor size on CT images which is not permanent and can shrink at a later time [27-
28]. As a result, there is a need for new approaches which is not entirely based on one-
dimensional size.  
In this study, we developed a CAD model which computes a number of 159 
quantitative image features to estimate the tumor shape, size, density and texture 
characteristics. Two sets of the quantitative features, pre-treatment and pre-post treatment 
features, were computed by our new CAD scheme to predict the response of ovarian 
cancer patients to chemotherapy. The results indicate that the pre-and pre-post treatment 
features are able to yield AUC values of 0.8103 ± 0.0447 and 0.8292 ± 0.0431 
respectively, which is significantly higher than the results accomplished by the 
conventional RECIST method. The performance superiority can be attributed by two 
main advantages of our new method.  
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First, this study indicates that pre-therapy CT imaging data includes useful 
information for the therapy response prediction. The study supports the concept of 
emerging Radiomics, which hypothesizes that the tumor heterogeneity features detected 
and quantified from radiographic images (e.g., CT) enable to phenotype corresponding 
genomic or biological biomarkers to predict cancer prognosis or tumor response to the 
therapies [18]. In this study, we found that a number of tumor density and texture 
heterogeneity related image features, had significantly higher discriminatory or 
prediction power than random guess (AUC = 0.5). As indicated in Table 4, the highest 
AUC value of 0.6842 ± 0.0557 was achieved using one image feature computed from the 
pre-therapy CT images. Furthermore, by fusing a cluster of four selected optimal features 
using a simple equal-weighting method, the prediction performance significantly 
increased to 0.8103±0.0447 (p < 0.05). After applying an operation threshold, this fusion 
image marker achieved an overall prediction accuracy of 71%. In addition, this is a totally 
different approach of using RECIST in current clinical practice, which requires 
comparison of tumor size change in two sets of CT images acquired pre- and post-therapy. 
Thus, one potential advantage of using quantitative image feature analysis is enabling to 
predict or assess cancer prognosis or PFS before therapy. If successful, this will help 
clinicians (e.g., oncologists) select optimal or personized cancer treatment strategy for 
the individual patients to achieve the maximum therapy benefit while minimizing 
unnecessary toxicity. 
Second, our study also showed that although using pre-therapy CT images can 
help predict patients’ response to therapy, adding quantitative images features computed 
from post-therapy CT images could provide more discriminatory information. As a result, 
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many individual image features computed from pre- and post-therapy CT images yielded 
significantly higher prediction performance than using the image features computed from 
pre-therapy CT images only. In addition, comparing to using RECIST which yielded 74% 
prediction accuracy in this study, the overall prediction accuracy of using quantitative 
imaging marker increased to 80%. The higher performance is probably due to the fact 
that quantitative image feature analysis method is able to extract more useful information 
of tumor characteristic change from the CT images (i.e., tumor volume, density, boundary 
spiculation). RECIST, however, only assesses one dimension tumor size change from two 
sets of CT images. As shown in Table 5, besides tumor volume change, other 19 selected 
features with higher discriminatory power cover more tumor characteristics related to 
tumor shape (compactness-1) and density heterogeneity changes. This can be attributed 
by the fact that the chemotherapy treatment will not only lead to the change of the tumor 
size, but also result in the change of some other tumor characteristics, such as the tumor 
density, necrosis, stiffness and other heterogeneity patterns. Many of these characteristic 
changes will not be reflected on the tumor size measurement, but can be extracted by 
quantitative image feature analysis. Because of these facts, quantitative image feature 
analysis is a new promising approach to more accurately predict patients’ response to 
therapies.  
Even though the results are encouraging, this study has some limitations. First, 
we noticed that although adding the post-therapy CT image data can significantly 
improve the predicting performance on the single feature (e.g., 0.7705 ± 0.0495 vs 0.6842 
± 0.0557), the performance improvement between using two fusion based image markers 
was not substantial (e.g., 0.8292 ± 0.0431 vs 0.8103 ± 0.0447). The reason behind this 
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observation needs to be further investigated using other independent image datasets. 
Second, due to the limited size of our image dataset, only a simple equal weighted fusion 
method was applied to build image marker. In the future study, a large image dataset 
needs to be built and the state of the art machine learning methods need to be investigated 
to optimally combine image features to further improve the predicting performance. 
Third, for each case, we only investigated the tumors marked and tracked by the 
radiologist based on RECIST guideline. For the features of these different tracked tumors, 
we only computed the average value as the final case-based feature, which might not be 
the optimal method. Thus, we still need to investigate the more effective algorithms to 
quantify the case-based image features. Fourth, in this dataset, the patient cases were not 
classified with different chemotherapy drugs. Given that the tumor responsive to a certain 
type of drug may contain some specific tumor characteristics, dividing and finding the 
best features for the patients with different therapy groups may further improve the 
predicting accuracy. Last, although we have accumulated 91 cancer cases, the robustness 
of our experiment results need to be tested and verified using large and diverse image 
datasets in the future.  
In conclusion, even with few limitations, we believe that this initial study is 
unique and valid, which demonstrated that pre-therapy CT image analysis provide useful 
information in predicting ovarian cancer patients response to chemotherapy and addition 
of post-therapy information can further improve the model effectiveness by generating 
higher prediction accuracy than both pre-therapy and conventional RECIST criteria 
methods. As a result, this study provides a valid foundation for us to continue developing 
more robust quantitative image analysis scheme to identify clinically useful imaging 
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markers, which can more accurately predict the clinical benefit of the chemotherapy at 
the early stage for ovarian and/or other cancer patients. 
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